Avadel Pharmaceuticals plc (AVDL) Showcases LUMRYZ Success with 14 Abstracts, 4 Oral Presentations at SLEEP 2025
Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced it will present 14 new abstracts, including four oral presentations, at SLEEP 2025, highlighting significant advances for LUMRYZ, its once-at-bedtime sodium oxybate treatment for narcolepsy.
Interim results from the real-world REFRESH study showed that patients switching from twice-nightly oxybate to LUMRYZ experienced clinically meaningful improvements in excessive daytime sleepiness (EDS), with many achieving normal Epworth Sleepiness Scale (ESS) scores.
A scientist in a labcoat examining a vial of experimental biopharmaceuticals.
Additional analyses from the pivotal Phase 3 REST-ON trial revealed that even those with the most severe baseline sleepiness saw their ESS scores normalize after 13 weeks on LUMRYZ, and the therapy did not worsen sleep apnea. Further data demonstrated a reduction in distressing hallucinations and improvement in sleep-related eating disorder (SRED) symptoms after switching to LUMRYZ. Long-term tolerability was underscored, with only 4% discontinuing due to side effects.
Avadel Pharmaceuticals plc (NASDAQ:AVDL) emphasized that LUMRYZ, FDA-approved for adults and children aged 7 and older, offers a major benefit over traditional oxybate by eliminating the need for middle-of-the-night dosing, supporting better sleep continuity and patient care.
With these compelling results, Avadel Pharmaceuticals plc (NASDAQ:AVDL) continues to solidify its leadership in innovative narcolepsy treatments.
While we acknowledge the potential of AVDL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVDL and that has 100x upside potential, check out our report about this
READ NEXT: and
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Among youths, are night owls more impulsive than morning larks?
Among adolescents, night owls appear to be more impulsive than their morning lark peers, according to a new study being presented at the SLEEP 2025 annual conference in Seattle. Those with a self-reported preference for staying up late and sleeping in — the night owls — reported 'greater negative urgency and lack of perseverance, which are two aspects of impulsivity,' according to material from the American Academy of Sleep Medicine. The release said they were more apt to act impulsively when they experienced negative emotions and they quit tasks that felt difficult. But when objective measurements of circadian phase were used, the research didn't find an association between sleep-time preference and impulsivity. 'Surprisingly, we did not find a significant link between dim light melatonin onset and impulsivity in our sample,' said lead author Riya Mirchandaney, a doctoral candidate in clinical-health psychology at the University of Pittsburgh. 'This suggests that there may be unmeasured psychological or behavioral factors influencing both impulsivity and the self-assessment of circadian preference, regardless of the timing of an individual's internal circadian clock.' The academy describes circadian rhythms as biological rhythms that all living organisms have. It's a body clock synchronized to a 24-hour light-dark cycle. 'Circadian preference reflects an individual's desired timing of sleep and wake, and circadian timing can be objectively measured by analyzing saliva or blood plasma to detect dim light melatonin onset,' the group notes. More than 200 adolescents took part in the research across two different studies. They were average age of 17 and just over 6 in 10 were female. The study relied on self-reported assessments of impulsivity and circadian preference, then lab samples of saliva were used to assess biological circadian phase by looking at dim light melatonin onset. For a week, the participants also wore a wrist device to estimate their sleep midpoint and sleep duration. Each also completed an assessment of impulsivity at bedtime. Mirchandaney said the results might one day be used to study how to help teens temper impulsivity, 'a well-established contributor to alcohol and substance use,' per the release. The researchers believe that adolescence could be a valuable developmental period for using therapeutic interventions to advance sleep and circadian timing. The National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism both contributed to funding the study. Its abstract was published in an online supplement of the journal Sleep. Other studies back up the link between adolescent sleep and impulsive behaviors. For example, in 2019, a study from Sweden published in Sleep Medicine: X reported a 'bidirectional' link between adolescent sleep problems and impulsive behaviors over time. 'Youths who experienced sleep problems also experienced increased difficulties with impulse control, and problems regulating impulses were also linked with increases in sleep problems, and these effects were systematic over two years. Moreover, age did not moderate these associations but impulsive behaviors had a larger impact on girls' insomnia as compared to boys,' per that study. Johns Hopkins University has reported that 'teens love to label themselves 'night owls,' trading stories of all-nighters and sleeping away an entire Saturday.' The article notes that adolescent and teen years are a time when a natural shift in circadian rhythm occurs, so they are frequently wide awake at 11 p.m. and then sleep-deprived because of school start times and homework and other activities. Pediatrician Dr. Michael Crocetti reported that teens need between nine and nine-and-a-half hours of sleep, which is an hour more than they needed when they were 10. The extra hour — if they actually get it — helps with growth, brain development and also protects from some serious consequences like depression and poor choices like drug use. That article ties in some suggestions to encourage more sleep among teens, including starting the day with a burst of sunshine, linking car privileges to good sleep, encouraging afternoon naps and banning texting from the bedroom, among other things. The experts at Johns Hopkins also suggest avoiding a drastic summer shift of pushing the sleep schedule too far off track because school's out. That could make it very hard to get back on track when school resumes. But it could also create other issues, like moodiness or excessive sleepiness during the day. There are other reasons to ponder youthful sleep patterns, including the fact that bad habits formed early may stick or create long-lasting challenges. And it's not just among adolescents, either. As Deseret News reported in 2022, night owls may be more apt to develop heart disease or diabetes than are the morning larks. And those who rise early 'seem to burn more fat as an energy source and are often more active than those who stay up late.' Those are findings from Rutgers University, published in the journal Experimental Physiology. The study said the two groups were similar in body composition, but the early risers were more sensitive to insulin levels in their blood and burned fat better while exercising and resting. Night owls didn't burn as much fat for energy; they used carbohydrates.
Yahoo
4 days ago
- Yahoo
Avadel Pharmaceuticals plc (AVDL) Showcases LUMRYZ Success with 14 Abstracts, 4 Oral Presentations at SLEEP 2025
Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced it will present 14 new abstracts, including four oral presentations, at SLEEP 2025, highlighting significant advances for LUMRYZ, its once-at-bedtime sodium oxybate treatment for narcolepsy. Interim results from the real-world REFRESH study showed that patients switching from twice-nightly oxybate to LUMRYZ experienced clinically meaningful improvements in excessive daytime sleepiness (EDS), with many achieving normal Epworth Sleepiness Scale (ESS) scores. A scientist in a labcoat examining a vial of experimental biopharmaceuticals. Additional analyses from the pivotal Phase 3 REST-ON trial revealed that even those with the most severe baseline sleepiness saw their ESS scores normalize after 13 weeks on LUMRYZ, and the therapy did not worsen sleep apnea. Further data demonstrated a reduction in distressing hallucinations and improvement in sleep-related eating disorder (SRED) symptoms after switching to LUMRYZ. Long-term tolerability was underscored, with only 4% discontinuing due to side effects. Avadel Pharmaceuticals plc (NASDAQ:AVDL) emphasized that LUMRYZ, FDA-approved for adults and children aged 7 and older, offers a major benefit over traditional oxybate by eliminating the need for middle-of-the-night dosing, supporting better sleep continuity and patient care. With these compelling results, Avadel Pharmaceuticals plc (NASDAQ:AVDL) continues to solidify its leadership in innovative narcolepsy treatments. While we acknowledge the potential of AVDL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVDL and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Business Wire
4 days ago
- Business Wire
ESS Confirms Path to Continued Execution of its Strategic Plan with the Energy Base
WILSONVILLE, Ore.--(BUSINESS WIRE)--ESS Tech, Inc. ('ESS' or the 'Company') (NYSE:GWH), a leading manufacturer of iron flow long-duration energy storage (LDES) systems for commercial- and utility-scale applications, today provided a business update and the continued execution of its strategic plan focused around the Energy Base product. Previously, ESS announced the potential need to take certain workforce actions in the event it was unable to raise capital to enable the Company to avoid or postpone a shutdown. ESS subsequently received sufficient capital not anticipated in the ordinary course of business to continue operations at its Wilsonville facility in the near term, though it will still undertake actions to judiciously manage its operating expenses. 'I am pleased to report this important development and the continuation of our strategic pivot and delivery of a scalable Energy Base solution manufactured here in the United States to support unprecedented growth in energy demand and the critical need for grid reliability and resiliency,' said Kelly Goodman, Interim CEO of ESS. ESS also recently executed several actions to further implement this plan and deepen collaboration with key partners. The Company closed orders for the sale of four Energy Warehouses as part of its ongoing dual strategy to move existing inventory and pivot to a focused Energy Base product offering. ESS intends to sell the associated Advanced Manufacturing Production Tax Credits (PTC) from the equipment sales this quarter. The Company is continuing discussions with potential capital providers and exploring all available financing options to support its repositioned business plan, including to close key customer contracts for its proprietary 10+ hour Energy Base product. About ESS Tech, Inc. At ESS (NYSE: GWH), our mission is to accelerate global decarbonization by providing safe, sustainable, long-duration energy storage that powers people, communities and businesses with clean, renewable energy anytime and anywhere it's needed. As more renewable energy is added to the grid, long- duration energy storage is essential to providing the reliability and resiliency we need when the sun is not shining, and the wind is not blowing. Our technology uses earth-abundant iron, salt and water to deliver environmentally safe solutions capable of providing up to 12 hours of flexible energy capacity for commercial and utility-scale energy storage applications. Established in 2011, ESS enables project developers, independent power producers, utilities and other large energy users to deploy reliable, sustainable long-duration energy storage solutions. For more information visit This release contains certain forward-looking statements, including statements regarding the Company and its management team's expectations, hopes, beliefs, intentions or strategies regarding the future. The words 'anticipate', 'believe', 'continue', 'could', 'estimate', 'expect', 'intends', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'should', 'will' and 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Examples of forward-looking statements include, among others, statements regarding operations at the Company's Wilsonville site, measures to manage operating expenses, the sale of Production Tax Credits, contracts and relationships with third parties and potential capital raising measures. These forward-looking statements are based on the Company's current expectations and beliefs concerning future developments and their potential effects on the Company and involve a number of risks, uncertainties (some of which are beyond the Company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, which include, but are not limited to, partnerships and customer relationships not resulting in expectant benefits, the Company's inability to sell its Production Tax Credits, and the Company's inability to raise additional capital and other risks and uncertainties described more fully in the section titled 'Risk Factors' in the Company's Quarterly Report on Form 10-Q filed on May 15, 2025, and the Company's other filings with the U.S. Securities and Exchange Commission. Except as required by law, the Company is not undertaking any obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
